Abstract
In 2004, the first nonpeptide selective angiotensin II type 2 receptor (AT2R) agonist was reported. This nonpeptide (C21), which, exerts anti-inflammatory and antifibrotic actions in vivo, has been extensively explored and is currently in clinical trials. Subsequently, a large number of related drug-like AT2R agonists have been disclosed. Reviews that summarize known structure-activity relationships (SAR) of nonpeptide AT2R agonists have recently appeared in the literature; however, very few reviews discuss the role of angiotensin peptides as AT2R agonists. Furthermore, to date, there have been no reports focusing on the medicinal chemistry perspective of peptide AT2R agonists. In the present review, reports on linear and conformationally constrained Ang II analogues, with a focus on AT2R selective ligands that are proven to act as agonists at the AT2 receptor are summarized. The impact of truncations and macrocyclizations of Ang II analogues and of incorporation of scaffolds that mimic secondary structures into Ang II related peptides is highlighted. A survey of the efforts to transform the nonselective octapeptide Ang II to more drug-like selective AT2R agonists is presented. The relationship between the structures of the AT2R agonists and their affinity to the AT2R is briefly discussed and common pharmacophore elements of AT2R selective Ang II peptide analogues and selective nonpeptide AT2R agonists are compared.
Keywords: Angiotensin II, AT2 receptor agonist, peptide, peptidemimetic, secondary structure mimetic, bioactive conformation.
Current Protein & Peptide Science
Title:Angiotensin Peptides as AT2 Receptor Agonists
Volume: 18 Issue: 8
Author(s): Mathias Hallberg*, Jonas Sävmarker and Anders Hallberg
Affiliation:
- Beijer Laboratory, Department of Pharmaceutical Biosciences, Division of Biological Research on Drug Dependence, BMC, Uppsala University, P.O. Box 591, SE751 24 Uppsala,Sweden
Keywords: Angiotensin II, AT2 receptor agonist, peptide, peptidemimetic, secondary structure mimetic, bioactive conformation.
Abstract: In 2004, the first nonpeptide selective angiotensin II type 2 receptor (AT2R) agonist was reported. This nonpeptide (C21), which, exerts anti-inflammatory and antifibrotic actions in vivo, has been extensively explored and is currently in clinical trials. Subsequently, a large number of related drug-like AT2R agonists have been disclosed. Reviews that summarize known structure-activity relationships (SAR) of nonpeptide AT2R agonists have recently appeared in the literature; however, very few reviews discuss the role of angiotensin peptides as AT2R agonists. Furthermore, to date, there have been no reports focusing on the medicinal chemistry perspective of peptide AT2R agonists. In the present review, reports on linear and conformationally constrained Ang II analogues, with a focus on AT2R selective ligands that are proven to act as agonists at the AT2 receptor are summarized. The impact of truncations and macrocyclizations of Ang II analogues and of incorporation of scaffolds that mimic secondary structures into Ang II related peptides is highlighted. A survey of the efforts to transform the nonselective octapeptide Ang II to more drug-like selective AT2R agonists is presented. The relationship between the structures of the AT2R agonists and their affinity to the AT2R is briefly discussed and common pharmacophore elements of AT2R selective Ang II peptide analogues and selective nonpeptide AT2R agonists are compared.
Export Options
About this article
Cite this article as:
Hallberg Mathias*, Sävmarker Jonas and Hallberg Anders, Angiotensin Peptides as AT2 Receptor Agonists, Current Protein & Peptide Science 2017; 18 (8) . https://dx.doi.org/10.2174/1389203718666170203150344
DOI https://dx.doi.org/10.2174/1389203718666170203150344 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment Options for Post-Transplantation Diabetes Mellitus
Current Diabetes Reviews Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Current Progress in Non-Invasive Imaging of Beta Cell Mass of the Endocrine Pancreas
Current Medicinal Chemistry Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery MicroRNAs in Diabetic β Cell Dysfunction and their Role as Biomarkers
Current Signal Transduction Therapy The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Mitochondria: A Novel Therapeutic Target in Diabetic Nephropathy
Current Medicinal Chemistry Faujasiopsis flexuosa (Lam.) C. Jeffrey (Asteraceae) – A Promising Traditionally used Endemic Medicinal Plant from Mauritius
Current Traditional Medicine Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance
Current Pharmaceutical Design Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Raxofelast, (±)5-(Acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic Acid: A New Antioxidant to Modulate the Inflammatory Response During Ischemia-Reperfusion Injury and Impaired Wound Healing
Mini-Reviews in Medicinal Chemistry Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Systematic Evaluation of the Mechanisms of Mulberry Leaf (Morus alba Linne) Acting on Diabetes Based on Network Pharmacology and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use
Current Drug Safety The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Inflammation, Adipocytokines, and Atherosclerosis in the Metabolic Syndrome
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued)